NCT00069264View on ClinicalTrials.gov

Study of E7389 in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

September 30, 2003

Primary Completion Date

March 31, 2005

Study Completion Date

July 31, 2005

Conditions
Advanced Solid Tumors
Interventions
DRUG

E7389

E7389 Dose-escalation starting at 0.25 mg/m\^2 intravenous on Days 1, 8, and 15 of a 28 day cycle.

Trial Locations (2)

10461

The Bronx

Unknown

San Antonio

All Listed Sponsors
lead

Eisai Inc.

INDUSTRY

NCT00069264 - Study of E7389 in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter